A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
University Hospital Southampton NHS Foundation Trust
Merck Sharp & Dohme LLC
University of Southampton
Konkuk University Medical Center
Newcastle-upon-Tyne Hospitals NHS Trust
University College, London
University College, London
University Hospital Plymouth NHS Trust
National Cancer Institute (NCI)
National Cancer Institute (NCI)